PLUS1
19.01
-0.42 (-2.16%)
-0.42 (-2.16%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cassava Sciences Inc | SAVA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.42 | -2.16% | 19.01 | 19:05:28 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.50 | 17.35 | 23.70 | 19.75 | 19.43 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 19.01 | 19.75 | 0.74 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 42,121 | 7,066,225 | $ 20.59 | $ 145,522,841 | 2,693,419 | 1.11 - 23.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:08:00 | formt | 100 | $ 19.01 | USD |
Cassava Sciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 664.47M | 34.95M | 33.13M | $ - | $ - | -0.27 | -51.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cassava Sciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/04/2021 | 08:30 | GlobeNewswire Inc. | Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical.. |
| 12/14/2020 | 17:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/14/2020 | 17:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/11/2020 | 16:44 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/27/2020 | 08:30 | GlobeNewswire Inc. | USAN Modifies Lead Drug Candidate’s Chemical Name to.. |
| 11/23/2020 | 10:04 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 11/13/2020 | 16:37 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAVA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.605 | 23.70 | 11.64 | 16.05 | 3,729,245 | 6.41 | 50.81% |
| 1 Month | 6.86 | 23.70 | 6.7186 | 12.08 | 3,820,433 | 12.15 | 177.11% |
| 3 Months | 10.38 | 23.70 | 6.70 | 10.37 | 3,546,492 | 8.63 | 83.14% |
| 6 Months | 3.58 | 23.70 | 2.78 | 8.97 | 5,228,048 | 15.43 | 431.01% |
| 1 Year | 6.93 | 23.70 | 1.11 | 7.27 | 3,941,661 | 12.08 | 174.31% |
| 3 Years | 1.21 | 23.70 | 1.00 | 6.83 | 2,853,091 | 17.80 | 1,471.07% |
| 5 Years | 1.21 | 23.70 | 1.00 | 6.83 | 2,853,091 | 17.80 | 1,471.07% |
Cassava Sciences Description
| Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. It is also developing an experimental biomarker diagnostic PTI-125 to detect Alzheimer's disease with the help of a blood test. |
